Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Maurizio Paciaroni, Birsen Ince, Bo Hu...
https://pubmed.ncbi.nlm.nih.gov/31867054/Actively Recruiting
Led by Kafrelsheikh University · Updated on 2025-09-05
600
Participants Needed
1
Research Sites
3 weeks
Total Duration
Researchers are studying the impact of adding atorvastatin or rosuvastatin within the first 24 hours to clopidogrel treatment in patients experiencing their first large-vessel ischemic stroke. This trial aims to assess clinical outcomes using stroke severity and disability scales, along with monitoring for possible side effects. The study is a randomized controlled trial conducted by Kafrelsheikh University and focuses on patients aged 18 to 75 years. Participants are divided into two groups one group receives 40 mg of atorvastatin daily along with clopidogrel, and the other group receives 20 mg of rosuvastatin daily with the same clopidogrel regimen. Both statins are given for three months, while clopidogrel is started with a 300 mg loading dose followed by 75 mg daily for the entire treatment period. The trial includes clinical assessments, imaging scans, blood tests, and heart monitoring to evaluate stroke effects and safety. During the study, patients undergo evaluations including the National Institute of Health Stroke Scale NIHSS at admission and day 7, and the Modified Rankin Scale mRS at one week and three months. Imaging tests include CT and MRI brain scans with stroke protocols and vascular assessments. Blood tests check liver function, inflammation, and muscle enzymes to monitor for adverse effects. The main outcome is the rate of new strokes at 90 days, with additional measures of stroke severity, functional recovery, cardiovascular events, and drug safety over the three-month period.
CONDITIONS
Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke
M
mohamed G. Zeinhom, MD
S
sherihan R. ahmed, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Kafrelsheikh University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 months
Participants receive daily oral treatment with either 40 mg atorvastatin or 20 mg rosuvastatin along with clopidogrel (a loading dose of 300 mg followed by 75 mg daily) for 3 months.
Visits on admission, day 7, and at 3 months for clinical assessments and follow-up
Duration - Up to 3 months after treatment start
Participants are followed to monitor for new stroke events, assess clinical outcomes using the NIH Stroke Scale and Modified Rankin Scale, and evaluate treatment safety including liver and muscle function tests.
Face-to-face visits at 1 week and 3 months
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Maurizio Paciaroni, Birsen Ince, Bo Hu...
https://pubmed.ncbi.nlm.nih.gov/31867054/Alan D Lopez, Colin D Mathers, Majid Ezzati...
https://pubmed.ncbi.nlm.nih.gov/16731270/Mohamed G Zeinhom, Hany M Aref, Hala El-Khawas...
https://pubmed.ncbi.nlm.nih.gov/34515113/Kafrelsheikh University
Lead Sponsor